Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Tarsus Pharmaceuticals ( (TARS) ).
On June 12, 2025, Tarsus Pharmaceuticals, Inc. held its Annual Meeting of Stockholders where several key proposals were voted upon. The stockholders elected two Class II directors, approved executive compensation on a non-binding basis, decided on an annual frequency for future compensation votes, and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025.
The most recent analyst rating on (TARS) stock is a Buy with a $73.00 price target. To see the full list of analyst forecasts on Tarsus Pharmaceuticals stock, see the TARS Stock Forecast page.
Spark’s Take on TARS Stock
According to Spark, TipRanks’ AI Analyst, TARS is a Neutral.
Tarsus Pharmaceuticals’ overall stock score reflects a mix of strong sales growth and strategic initiatives against the backdrop of financial challenges. The earnings call was a bright spot, showcasing positive developments, but technical and valuation metrics highlight ongoing risks.
To see Spark’s full report on TARS stock, click here.
More about Tarsus Pharmaceuticals
Average Trading Volume: 673,215
Technical Sentiment Signal: Buy
Current Market Cap: $1.73B
See more insights into TARS stock on TipRanks’ Stock Analysis page.